Patients with acute graft-versus-host disease (GVHD) that does not respond to steroid therapy are more likely to respond to the drug ruxolitinib (Jakafi) than other available treatments, results from a large clinical trial show.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2zG9tIA
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2zG9tIA